Abcam (LON:ABC)‘s stock had its “hold” rating reissued by equities researchers at Peel Hunt in a research note issued on Thursday.
Other analysts have also recently issued research reports about the stock. Berenberg Bank cut shares of Abcam to a “hold” rating and decreased their target price for the stock from GBX 1,240 ($16.82) to GBX 1,230 ($16.68) in a research note on Monday, March 5th. JPMorgan Chase boosted their target price on shares of Abcam from GBX 946 ($12.83) to GBX 1,011 ($13.71) and gave the stock a “neutral” rating in a research note on Thursday, March 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of GBX 1,135.25 ($15.40).
Abcam opened at GBX 1,250 ($16.96) on Thursday, according to MarketBeat.com. Abcam has a fifty-two week low of GBX 9.73 ($0.13) and a fifty-two week high of GBX 1,290 ($17.50).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.